← Leaderboards
Peter Donofrio
Wake Forest University Health Sciences
$85,536
Attributed
$85,536
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$85,536 · 2
By mechanism
M01$85,536 · 2
Top collaborators
No co-investigators on record.
Most similar at Wake Forest University Health Sciences
Same institution · by research overlap
- Carol Milligan$8,862,776
- Marco Pahor$75,096,124
- Ronald W Oppenheim$7,349,405
- Joseph Arnold Skelton$3,845,681
- Carol C Cunningham$1,628,710
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationClinical TrialsNervous System Disorder ChemotherapyAmyotrophic Lateral SclerosisPatient Oriented ResearchClinical ResearchHuman SubjectUbiquinoneCyclooxygenase InhibitorsFree RadicalsMitochondriaNonsteroidal Antiinflammatory AgentAdenosine Triphosphate
Grant awards (4)
CLINICAL TRIAL OF CELEBREX IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS$7,193
M01 · FY2005 · RR
CLINICAL TRIAL OF COENZYME Q10 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS$7,193
M01 · FY2005 · RR
Clinical Trial of Celebrex in Subjects with Amyotrophic Lateral Sclerosis$44,149
M01 · FY2004 · RR
Clinical Trial of Coenzyme Q10 in Patients with Amyotrophic Lateral Sclerosis$27,001
M01 · FY2004 · RR